Interleukin-6 and the acute phase response during treatment of patients with paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

Schweitzer, Dave H.; Ruit, Marjanne Oostendorp-van de; Pluijm, Gabri van der; Löwik, Clemens W.G.M.; Papapoulos, Socrates E.

doi:10.1002/jbmr.5650100617

Cited by 140 publications

(42 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, another study has demonstrated that zoledronate did not reduce the population of osteoclast precursor after 18 months of treatment in osteopenic women, (27) There are also conflicting in vitro data regarding the effect of bisphosphonates on osteoclastogenic cytokines such as IL-1, TNF and circulating levels of RANKL and osteoprotegerin (OPG) (28)(29)(30)(31)). RANKL is produced by the osteoblasts and binds to the receptor RANK which is located on the osteoclast precursor cells as well as the mature osteoclast (32).…”

Section: Introductionmentioning

confidence: 99%

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

Gossiel

Hoyle

McCloskey

et al. 2016

Bone

View full text Add to dashboard Cite

Bisphosphonates are used to treat bone disease characterised by increased bone resorption by inhibiting the activity of mature osteoclasts, resulting in decreased bone turnover.Bisphosphonates may also reduce the population of osteoclast precursor cells. Our aims were to investigate the effect of bisphosphonates on i) osteoclast precursor cells and ii) circulating cytokine and cytokine receptor in postmenopausal women with osteoporosis compared with healthy premenopausal women. Participants were 62 postmenopausal women (mean age 66) from a 48-week parallel group trial of bisphosphonates. They received ibandronate 150mg/month (n=22), alendronate 70mg/week (n=19) or risedronate 35mg/week (n=21). Fasting blood was collected at baseline, weeks 1 and 48. At baseline, blood was also collected from 25 healthy premenopausal women (mean age 37) to constitute a control group. Peripheral blood mononuclear cells were extracted and stained for CD14, M-CSFR, CD11b and TNFRII receptors. Flow cytometry was used to identify cells expressing CD14+ and M-CSF+ or CD11b+ or TNFRII+. RANKL and OPG were measured to evaluate potential mediation of the bisphosphonate effect. After 48 weeks of treatment, there was a decrease in the percentage of cells expressing M-CSFR and CD11b receptors by 53% and 49% respectively (p<0.01). Cells expressing M-CSFR and CD11b were decreased with ibandronate and risedronate after 48 weeks to the lower part of the premenopausal reference interval. These effects were not significantly different between each of the treatment groups. There was no significant effect on RANKL and OPG throughout the study period. Bisphosphonates inhibit bone resorption in the short-term by direct action on mature osteoclasts. There is also a later effect mediated in part by a reduction in the population of circulating osteoclast precursors.

show abstract

Section: Introductionmentioning

confidence: 99%

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

Gossiel

Hoyle

McCloskey

et al. 2016

Bone

View full text Add to dashboard Cite

show abstract

“…(1)(2)(3) The fever was noted to be associated with a fall in circulating lymphocyte number (1,4) and increases in circulating IL-6 (4) and tumor necrosis factor-alpha (TNF-a) (4)(5)(6) but not interleukin (IL)-1. (6) This is referred as the acute phase response (APR).…”

Section: Introductionmentioning

confidence: 99%

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration

Rossini

Adami

Viapiana

et al. 2011

Journal of Bone and Mineral Research

View full text Add to dashboard Cite

The use of intravenous nitrogen-containing bisphosphonates (N-BPs) is associated with the appearance of an acute phase response (APR) in a proportion of the patients for reasons that are poorly understood. The APR was attributed to the indirect activation of gd T cells with the release of interferon-g and tumor necrosis factor (TNF). Forty patients with postmenopausal or senile osteoporosis (age range ¼ 53-91 years) never previously treated with intravenous (iv) bisphosphonate, received a single 5-mg zoledronic acid (ZOL) iv infusion over 15 minutes. White blood cells were counted and analyzed with an automated hematology analyzer (ADVIA 2120i Siemens, New York, USA) and by flow cytometer (BD FACSCanto, Becton Dickinson). The occurrence of APR was defined by the occurrence of fever (>37 8C) during the next 2 days. Forty-two percent of patients (17 of 40) receiving the infusion of ZOL experienced an APR. Compared with the others they were younger (69 AE 7 years versus 74 AE 8 years; p ¼ 0.06), and both the proportion and absolute number of gd T cells were significant higher ( p ¼ 0.02 and p ¼ 0.013, respectively). Nonsignificant differences were found between the two groups for white blood cells and for the other circulating lymphocyte subpopulations. Age was inversely correlated with circulating gd T cells (p ¼ 0.003) but the difference between the two groups in circulating gd T cells persisted for age-adjusted values and vice versa. In conclusion, the results of this study indicate that the number of circulating gd T cells, together with age, are important determinant of the occurrence of APR after intravenous infusion of ZOL and possibly of any other N-BPs. ß

show abstract

“…Внутривен-ный путь введения препарата является альтернативой для пациенток, слабо приверженных лечению пероральными бисфосфонатами, а также при наличии заболеваний верхних отделов желудочно-кишечного тракта. Но использование внутривенных форм БФ часто ассоциировано с развитием симптомов реакции острой фазы [4,11,12].…”

Section: Discussionunclassified

Treatment of Postmenopausal Osteoporosis With Nitrogen Containing Bisphosphonates, Early Side Effects and Their Prevention

Yakushevskaya¹,

Якушевская²,

Yureneva³

2013

Osteopor Bone Dis

View full text Add to dashboard Cite

Infusions of aminobisphosphonates are now established therapies ofpostmenopausal osteoporosis. Their use is associated with fever and musculoskeletal pain in some subjects, referred to as the acute phase response (APR). The purpose of the study was to explore tolerability of zoledronic acid in the treatment of postmenopausal osteoporosis. In a 36-month open label, prospective study patients with postmenopausal osteoporosis iv received zoledronic acid at a dose of 5 mg every 12 months. We then analyzed the tolerability of the treatment at the hospital and via telephone interviews during the next 14 days and every 3 months after the infusion. Prevention of APR was carried out with paracetamol 500 mg x 3 times a day on the day of first infusion and the next 2 days. Symptoms of APR were recorded in 39% (n=43) of patients with prevention therapy. APR developed in the first 12-24 hours after infusion of zoledronic acid. Among women without prevention APR developed in 65% (n=75) of cases. (OR=0.34 CI (0.2-0.59)). After the 2 nd infusion symptoms of APR were noted in 27.9% (n=26) (р<0.05) of 93 patients, after the 3 rdin 6.6% (n=2) of 30 patients. Thus, in >90% of cases the symptoms were of mild or moderate severity, with resolution within 3 days after infusion of zoledronic acid. The most frequent symptoms were bone and muscular manifestations and a flu-like syndrome (p<0.05). APR developed during the first 12-24 hours after infusion of zoledronic acid. ARR developed 2.5 times more often in the cases when zoledronic acid was used for the first time. If paracetamol treatment was administered, APR cases were documented 1.7 times less often with lesser degree and length of manifestations. Frequency of APR dropped after repeated zoledronic acid infusions.

show abstract

Interleukin-6 and the acute phase response during treatment of patients with paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate

Cited by 140 publications

References 24 publications

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

The effect of bisphosphonate treatment on osteoclast precursor cells in postmenopausal osteoporosis: The TRIO study

Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration

Treatment of Postmenopausal Osteoporosis With Nitrogen Containing Bisphosphonates, Early Side Effects and Their Prevention

Contact Info

Product

Resources

About